Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028”: [ESMO Open 10 (2025) 104295]

M. Donia; H. Jespersen; M. Jalving; R. Lee; H. Eriksson; C. Hoeller; M. Hernberg; I. Gavrilova; L. Kandolf; G. Liszkay; H. Helgadottir; A. Zhukavets; Dace Pjanova; I. Marquez-Rodas; B. Neyns; H. Westgeest; I. Pourmir; P. Sobczuk; E. Ellebaek; T. Amaral

doi:10.1016/j.esmoop.2025.105492

Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028”: [ESMO Open 10 (2025) 104295]

M. Donia (Corresponding Author)
, H. Jespersen
, M. Jalving
, R. Lee
, H. Eriksson
, C. Hoeller
, M. Hernberg
, I. Gavrilova
, L. Kandolf
, G. Liszkay
, H. Helgadottir
, A. Zhukavets
, Dace Pjanova
, I. Marquez-Rodas
, B. Neyns
, H. Westgeest
, I. Pourmir
, P. Sobczuk
, E. Ellebaek
, T. Amaral (Corresponding Author)

Rīga Stradiņš University

Research output: Contribution to journal › Erratum

Abstract

The authors regret that in the original publication the name of Dr Pjanova was spelled incorrectly; the correct spelling is now given above. Further, for the sentence “Overall, in the immediate future adjuvant treatment is expected to maintain its cornerstone role for a sizable proportion (>40%) of patients with stage ≥IIIB melanoma, in addition to the form indication in stage IIB/C (only primary tumor) and IIIA (micrometastatic regional nodal disease).” please read: “Overall, in the immediate future adjuvant treatment is expected to maintain its cornerstone role for a sizable proportion (>40%) of patients with stage ≥IIIB melanoma, in addition to the formal indication in stage IIB/C (only primary tumor) and IIIA (micrometastatic regional nodal disease).” The authors would like to apologise for any inconvenience caused.

Original language	English
Article number	105492
Journal	ESMO Open
Volume	11
Issue number	1
DOIs	https://doi.org/10.1016/j.esmoop.2025.105492
Publication status	Published - Jan 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

1.6 Biological sciences
3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1016/j.esmoop.2025.105492Licence: CC BY

Cite this

Donia, M., Jespersen, H., Jalving, M., Lee, R., Eriksson, H., Hoeller, C., Hernberg, M., Gavrilova, I., Kandolf, L., Liszkay, G., Helgadottir, H., Zhukavets, A., Pjanova, D., Marquez-Rodas, I., Neyns, B., Westgeest, H., Pourmir, I., Sobczuk, P., Ellebaek, E., & Amaral, T. (2026). Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028”: [ESMO Open 10 (2025) 104295] . ESMO Open, 11(1), Article 105492. https://doi.org/10.1016/j.esmoop.2025.105492

@article{a4fb8e2b029f47259ae2c1bf9efc220b,

title = "Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028”: [ESMO Open 10 (2025) 104295] ",

abstract = "The authors regret that in the original publication the name of Dr Pjanova was spelled incorrectly; the correct spelling is now given above. Further, for the sentence “Overall, in the immediate future adjuvant treatment is expected to maintain its cornerstone role for a sizable proportion (>40\%) of patients with stage ≥IIIB melanoma, in addition to the form indication in stage IIB/C (only primary tumor) and IIIA (micrometastatic regional nodal disease).” please read: “Overall, in the immediate future adjuvant treatment is expected to maintain its cornerstone role for a sizable proportion (>40\%) of patients with stage ≥IIIB melanoma, in addition to the formal indication in stage IIB/C (only primary tumor) and IIIA (micrometastatic regional nodal disease).” The authors would like to apologise for any inconvenience caused.",

author = "M. Donia and H. Jespersen and M. Jalving and R. Lee and H. Eriksson and C. Hoeller and M. Hernberg and I. Gavrilova and L. Kandolf and G. Liszkay and H. Helgadottir and A. Zhukavets and Dace Pjanova and I. Marquez-Rodas and B. Neyns and H. Westgeest and I. Pourmir and P. Sobczuk and E. Ellebaek and T. Amaral",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s)",

year = "2026",

month = jan,

doi = "10.1016/j.esmoop.2025.105492",

language = "English",

volume = "11",

journal = "ESMO Open",

issn = "2059-7029",

publisher = "Elsevier B.V.",

number = "1",

}

Donia, M, Jespersen, H, Jalving, M, Lee, R, Eriksson, H, Hoeller, C, Hernberg, M, Gavrilova, I, Kandolf, L, Liszkay, G, Helgadottir, H, Zhukavets, A, Pjanova, D, Marquez-Rodas, I, Neyns, B, Westgeest, H, Pourmir, I, Sobczuk, P, Ellebaek, E & Amaral, T 2026, 'Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028”: [ESMO Open 10 (2025) 104295] ', ESMO Open, vol. 11, no. 1, 105492. https://doi.org/10.1016/j.esmoop.2025.105492

TY - JOUR

T1 - Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma

T2 - current status and outlook to 2028”: [ESMO Open 10 (2025) 104295]

AU - Donia, M.

AU - Jespersen, H.

AU - Jalving, M.

AU - Lee, R.

AU - Eriksson, H.

AU - Hoeller, C.

AU - Hernberg, M.

AU - Gavrilova, I.

AU - Kandolf, L.

AU - Liszkay, G.

AU - Helgadottir, H.

AU - Zhukavets, A.

AU - Pjanova, Dace

AU - Marquez-Rodas, I.

AU - Neyns, B.

AU - Westgeest, H.

AU - Pourmir, I.

AU - Sobczuk, P.

AU - Ellebaek, E.

AU - Amaral, T.

PY - 2026/1

Y1 - 2026/1

N2 - The authors regret that in the original publication the name of Dr Pjanova was spelled incorrectly; the correct spelling is now given above. Further, for the sentence “Overall, in the immediate future adjuvant treatment is expected to maintain its cornerstone role for a sizable proportion (>40%) of patients with stage ≥IIIB melanoma, in addition to the form indication in stage IIB/C (only primary tumor) and IIIA (micrometastatic regional nodal disease).” please read: “Overall, in the immediate future adjuvant treatment is expected to maintain its cornerstone role for a sizable proportion (>40%) of patients with stage ≥IIIB melanoma, in addition to the formal indication in stage IIB/C (only primary tumor) and IIIA (micrometastatic regional nodal disease).” The authors would like to apologise for any inconvenience caused.

AB - The authors regret that in the original publication the name of Dr Pjanova was spelled incorrectly; the correct spelling is now given above. Further, for the sentence “Overall, in the immediate future adjuvant treatment is expected to maintain its cornerstone role for a sizable proportion (>40%) of patients with stage ≥IIIB melanoma, in addition to the form indication in stage IIB/C (only primary tumor) and IIIA (micrometastatic regional nodal disease).” please read: “Overall, in the immediate future adjuvant treatment is expected to maintain its cornerstone role for a sizable proportion (>40%) of patients with stage ≥IIIB melanoma, in addition to the formal indication in stage IIB/C (only primary tumor) and IIIA (micrometastatic regional nodal disease).” The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/105027134692

U2 - 10.1016/j.esmoop.2025.105492

DO - 10.1016/j.esmoop.2025.105492

M3 - Erratum

C2 - 41483632

AN - SCOPUS:105027134692

SN - 2059-7029

VL - 11

JO - ESMO Open

JF - ESMO Open

IS - 1

M1 - 105492

ER -

Corrigendum to “Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028”: [ESMO Open 10 (2025) 104295]

Abstract

UN SDGs

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this